Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 13/20 | 0.47 |
| ▸ | JAK2 | O60674 | 13/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 4/20 | 0.40 |
| ▸ | JAK3 | P52333 | 4/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495590 | 0.91 | AURKA (0.41) | JAK1JAK2IGF1RJAK3PRKCQ | |
| SCHEMBL3496244 | 0.90 | PRKCQ (0.50) | JAK1JAK2PRKCQAURKA | |
| SCHEMBL3496483 | 0.88 | CHEK1 (0.48) | IGF1RJAK3ALKAURKAFLT3 | |
| SCHEMBL3495099 | 0.81 | JAK2 (0.45) | JAK1JAK2IGF1RTYK2JAK3 | |
| SCHEMBL3493784 | 0.81 | JAK2 (0.45) | JAK1JAK2IGF1RTYK2JAK3 | |
| SCHEMBL3496178 | 0.79 | PAK1 (0.45) | JAK1JAK2TYK2JAK3PRKCQ | |
| SCHEMBL3495670 | 0.79 | JAK1 (0.44) | JAK1JAK2TYK2JAK3PRKCQ | |
| SCHEMBL3497098 | 0.79 | PRKCQ (0.46) | JAK1JAK2TYK2JAK3PRKCQ | |
| SCHEMBL3496552 | 0.78 | ALK (0.46) | JAK1JAK2ALK | |
| SCHEMBL3497975 | 0.78 | SYK (0.61) | JAK1JAK2PRKCQAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | JAK1 292/4885JAK2 268/4885IGF1R 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.